Ziihera (zanidatamab) Approved in Europe, Offering a New Option for HER2-Positive Cancer Treatment
Approval Background
On June 27, 2025, the European Medicines Agency (EMA) officially approved zanidatamab (Ziihera). This drug is a bispecific antibody for patients with HER2-positive cancer, possessing a distinct mechanism of action compared to existing treatments.
Clinical Evidence
In clinical trials, zanidatamab demonstrated excellent tumor suppression by simultaneously binding to two sites on HER2, and it showed improved response rates compared to existing treatments.
Positioning Compared to Competing Drugs
Currently, HER2-positive cancer treatments include trastuzumab and pertuzumab, but zanidatamab, with its bispecific structure, has the potential to provide an additional option for patients with resistance to existing therapies.
Reimbursement and Market Access Challenges
European national health authorities will determine reimbursement based on cost-effectiveness analyses, and the pricing policy and demonstration of clinical efficacy of zanidatamab will be crucial for reimbursement approval.
Future Prospects
Following approval, it is expected to be rapidly adopted in major cancer treatment centers, and the accumulation of real-world data will also be considered for expanding indications.
From an investor's perspective, zanidatamab, a differentiated bispecific antibody in the HER2-positive cancer treatment market, provides a new growth driver. For job seekers or industry professionals, this technology can be an important opportunity for the development of next-generation antibody platforms.
Source: EMA (ema)